ArticleThe oncologist2017

Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience.

Jasmeet C Singh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.